{
  "antimicrobial": {
    "name": "Antimicrobial Stewardship",
    "description": "Antimicrobial Stewardship is when an organisation promotes and monitors the correct use of antibiotics to ensure they remain effective in the future. The following measures are useful for monitoring antibiotic prescribing to support antimicrobial stewardship and reduce the threat of antimicrobial resistance."
  },
  "cardiovascular": {
    "name": "Cardiovascular system",
    "description": "These measures are for treatments commonly used for treating conditions affecting the cardiovascular system."
  },
  "centralnervous": {
    "name": "Central Nervous system",
    "description": "These measures are for treatments commonly used for treating conditions affecting the central nervous system."
  },
  "core": {
    "name": "Standard",
    "description": null
  },
  "cost": {
    "name": "Cost Saving",
    "description": "The following measures and an accumulation of all openprescribing.net measures where changes to prescribing in this area will result in cost savings. For more information on how OpenPrescribing can support identification of cost-saving opportunities please consult our <a href=\"https://ebmdatalab.net/qipp-planning-how-to/\">How-to guide</a>."
  },
  "diabetes": {
    "name": "Diabetes",
    "description": "These measures are for treatments commonly used for treating diabetes."
  },
  "efficacy": {
    "name": "Efficacy",
    "description": "Available evidence suggests that these treatments may not be effective or have more efficacious alternatives."
  },
  "erectiledysfunction": {
    "name": "Erectile Dysfunction",
    "description": "These measures are for treatments commonly used for treating erectile dysfunction."
  },
  "eye": {
    "name": "Eye",
    "description": "These measures are for treatments commonly used for treating conditions affecting the eye."
  },
  "gastrointestinal": {
    "name": "Gastrointestinal system",
    "description": "These measures are for treatments commonly used for treating conditions affecting the gastrointestinal system."
  },
  "generic": {
    "name": "Generic prescribing",
    "description": "The NHS has a policy of prescribing medicines by their generic name unless there is a clinical reason why the medicine must be prescribed by brand. Generic prescribing has saved the NHS significant amounts of money and is believed to be safer. The following measures identify medicines that should either be prescribed generically, or prescribed by brand for safety reasons."
  },
    "greenernhs": {
    "name": "Greener NHS",
    "description": "These measures support work to reduce the impact of medicines on overall enviromental impact of the NHS."
  },
  "infections": {
    "name": "Infections",
    "description": "These measures are for treatments commonly used for treating infections, including antibiotics and dressings."
  },
  "iif": {
    "name": "NHS England Investment and Impact Fund",
    "description": "The <a href=\"https://www.england.nhs.uk/wp-content/uploads/2020/02/update-to-the-gp-contract-agreement-2021-2324.pdf\">Investment and Impact Fund</a> is an NHS England scheme that rewards Primary Care Networks (PCNs) for delivering objectives in the NHS Long Term Plan. These measures are all included in the IIF and PCNs can use them to review the success of any interventions they make. Please note that some of the prescribing measures (e.g. gastroprotective prescribing) are not displayed here as the NHS does not publish the information, you can <a href=\"https://ebmdatalab.net/nhs-england-investment-and-impact-fund-a-new-dashboard-on-openprescribing/\">read more about this on our blog here</a>."
  },
  "lowpriority": {
    "name": "NHS England Low Priority",
    "description": [
      "This is a list of products",
      "considered a low priority for NHS Funding",
      "<a href=\"https://www.england.nhs.uk/medicines/items-which-should-not-be-routinely-prescribed/\">by NHS England</a>. For more information on how OpenPrescribing can support identification of cost-saving opportunities please consult our <a href=\"https://ebmdatalab.net/qipp-planning-how-to/\">How-to guide</a>."
    ]
  },
    "mentalhealth": {
    "name": "Mental Health",
    "description": "These measures are for treatments commonly used for treating mental health conditions."
  },
    "nice": {
    "name": "NICE",
    "description": "These measures are derived from guidance from the National Institute for Health and Care Excellence (NICE). This prescribing dashboard can be used to support implementation of NICE's recommendation through open audit and review."
  },
  "nutrition": {
    "name": "Nutrition",
    "description": "These measures are for treatments commonly used to improve nutrition."
  },
  "opioids": {
    "name": "Opioids",
    "description": "Opioids are painkillers and their use has been increasing in England <a href=\"https://www.thelancet.com/pdfs/journals/lanpsy/PIIS2215-0366(18)30471-1.pdf\"> (see paper)</a>. Although opioids provide effective analgesia for acute pain and in palliative care, there is little evidence of benefit for long-term opioids in most patients with persistent non-cancer pain, in terms of pain, quality of life or functioning, and they can have serious side-effects. These measures relate to the use of opioids and can be used to openly audit prescribing. More resources for reviewing prescribing are available at the <a href=\"https://www.rcoa.ac.uk/faculty-of-pain-medicine/opioids-aware\">Opioids Aware project</a>."
  },
  "pain": {
    "name": "Pain",
    "description": "These measures are for treatments commonly used for treating pain."
  },
  "paper": {
    "name": "Mentioned in Papers",
    "description": [
      "The below measures have been referenced in papers published by the EBM DataLab team."
    ]
  },
  "reproductive": {
    "name": "Reproductive system",
    "description": "These measures are for treatments commonly used for treating conditions affecting the reproductive system."
  },
  "respiratory": {
    "name": "Respiratory",
    "description": "These measures are for treatments commonly used for treating respiratory conditions such as asthma and COPD."
  },
  "safety": {
    "name": "Safety",
    "description": "Improving safety is about reducing risk and minimising mistakes. The World Health Organisation has launched its third patient safety challenge Medication Without Harm. Changes in the following measures may result in reduction of the risk of harm to patients and contribute to WHOs ambition in reducting medication related harm by 50% within 5 years."
  }
}
